Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $970.57 Average PT from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given a consensus rating of “Moderate Buy” by the twenty brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $976.41.

A number of equities analysts have weighed in on the company. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Truist Financial reissued a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $896.82 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a 50 day simple moving average of $953.01 and a 200 day simple moving average of $891.10. Regeneron Pharmaceuticals has a 52-week low of $684.80 and a 52-week high of $998.33. The firm has a market capitalization of $98.43 billion, a PE ratio of 25.81, a P/E/G ratio of 2.60 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the firm earned $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals will post 38.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock worth $13,124,641 in the last 90 days. Company insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Maryland State Retirement & Pension System boosted its stake in Regeneron Pharmaceuticals by 0.9% in the first quarter. Maryland State Retirement & Pension System now owns 8,048 shares of the biopharmaceutical company’s stock valued at $7,306,000 after buying an additional 68 shares in the last quarter. Mezzasalma Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 1.3% in the first quarter. Mezzasalma Advisors LLC now owns 2,533 shares of the biopharmaceutical company’s stock valued at $2,438,000 after buying an additional 33 shares in the last quarter. Marshall Financial Group LLC boosted its stake in Regeneron Pharmaceuticals by 9.7% in the first quarter. Marshall Financial Group LLC now owns 1,022 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 90 shares in the last quarter. FCG Investment Co boosted its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. FCG Investment Co now owns 754 shares of the biopharmaceutical company’s stock valued at $726,000 after buying an additional 31 shares in the last quarter. Finally, Retirement Guys Formula LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $1,148,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.